Mental Health

Westat Printer Friendly Version in PDF Format (3 PDF pages)

July 2019 Printer Friendly Version in PDF Format (47 PDF pages)

As the opioid epidemic has evolved into a national crisis, the need for treatment has increased greatly. Medication-assisted treatment (MAT) is a “whole-patient” approach to the treatment of opioid use disorder (OUD) that combines the use of medications and psychosocial supports, such as therapy, counseling, self-help groups, and case management.

Despite advances in the development of evidence-based treatment for adults with post-traumatic stress disorder (PTSD), the implementation of these treatments varies widely. To reduce this gap through wider dissemination of effective behavioral health treatment, the U.S.

Medicare beneficiaries in inpatient psychiatric facilities (IPFs) have complex conditions that require sustained engagement with physical and mental health care providers. People who receive care from IPFs are at risk for a range of negative health outcomes, but surprisingly little is known about their patterns of care.

Among employed adults, major depression is a leading cause of work absences (absenteeism) and impaired work performance (presenteeism) as well as short-term and long-term work disability. Depression is one of the largest and fastest growing categories of work disability claims filings in the public and private disability insurance sectors.

This report describes an extension of the RAND Corporation's evaluation of the Substance Abuse and Mental Health Services Administration's Primary and Behavioral Health Care Integration (PBHCI) grants program.

Winnie Chi, PhD, Emily Graf, BA, Landon Hughes, BA, Jean Hastie, MPH, Galina Khatutsky, MS, Sari B. Shuman, MPH, MSW, E. Andrew Jessup, and Sarita Karon, PhD RTI International Helen Lamont, PhD

Access to services, particularly behavioral health and substance use disorder (SUD) treatment services, is challenging in rural and other underserved areas.

This report summarizes financing and workforce policies that can be used by states to expand treatment access and capacity for opioid use disorder (OUD), focusing especially on medication-assisted treatment (MAT).